Effect of cholecalciferol supplementation on the clinical course of hospitalized COVID 19 patients
AbstractThe aim of this study was to evaluate the effect of cholecalciferol supplementation on the clinical course of hospitalized patients with moderate-to-severe COVID‑19. Results showed the baseline prevalence of a low 25-hydroxyvitamin D level. We demonstrated that 100 000 IU cholecalciferol supplementation in addition to the standard therapy is associated with a 25-hydroxyvitamin D level increase (average of 40.7%) as well as with the significantly higher levels of lymphocytes and neutrophils at the 9th day of hospitalization (p=0.047; p=0,025). Thus, vitamin D supplementation can be considered as an adjunctive treatment for COVID‑19.
Keywords:COVID 19; SARS-CoV 2; vitamin D; 25(OH)D; cholecalciferol
Funding. This work was financially supported by the Ministry of Science and Higher Education of the Russian Federation (Agreement No. 075-15-2022-301).
Conflict of interest. The authors declare no conflict of interest.
For citation: Mikhailova A.A., Lagutina D.I., Golovatyuk K.А. Effect of cholecalciferol supplementation on the clinical course of hospitalized COVID‑19 patients. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2022; 11 (3): 119–21. DOI: https://doi.org/10.33029/2304-9529-2022-11-3-119-121 (in Russian)